SIRT5 and inborn mitochondrial metabolism disorder: Therefore, the identification of SIRT5 small molecule agonists, including resveratrol derivatives BML-217 and MC3138[184,185], presents an effective therapeutic way to treat mitochondrial metabolic diseases and to relieve nerve injury.